 |
18 Diseases |  |
2 Trials |
|
2 Trials |  |
7 News |  |
- | OMS824 / Omeros
Enrollment change, Trial termination: Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease (clinicaltrials.gov) - Oct 22, 2018
P2, N=22, Terminated, Sponsor: Omeros Corporation
N=36 --> 22 | Suspended --> Terminated; Sponsor decision - pending further analysis of available data
- OMS824 / Omeros
Trial primary completion date: Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease (clinicaltrials.gov) - Apr 21, 2015
P2, N=36, Suspended, Sponsor: Omeros Corporation
N=36 --> 22 | Suspended --> Terminated; Sponsor decision - pending further analysis of available data Trial primary completion date: Mar 2015 --> Mar 2016
- OMS824 / Omeros
Trial suspension: Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease (clinicaltrials.gov) - Oct 22, 2014
P2, N=36, Suspended, Sponsor: Omeros Corporation
Trial primary completion date: Mar 2015 --> Mar 2016 Recruiting --> Suspended
- | OMS824 / Omeros
Enrollment change: Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease (clinicaltrials.gov) - Sep 12, 2014
P2, N=36, Recruiting, Sponsor: Omeros Corporation
Recruiting --> Suspended N=120 --> 36
- | OMS824 / Omeros
Trial completion, Enrollment change: Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects (clinicaltrials.gov) - Aug 15, 2014
P2, N=40, Completed, Sponsor: Omeros Corporation
N=120 --> 36 Recruiting --> Completed | N=32 --> 40
- ||||| OMS824 / Omeros
New P2 trial: Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease (clinicaltrials.gov) - Feb 26, 2014
P2, N=120, Recruiting, Sponsor: Omeros Corporation
- | OMS824 / Omeros
New P2 trial: Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects (clinicaltrials.gov) - Sep 25, 2013
P2, N=32, Recruiting, Sponsor: Omeros Corporation